What is evolocumab used for?
Evolocumab (brand name Repatha) is a cholesterol-lowering medicine in the PCSK9 inhibitor class. It’s used to reduce LDL (“bad”) cholesterol in people who need additional LDL lowering beyond statins and other lipid therapies. It’s also used in certain inherited high-cholesterol conditions and for patients at high cardiovascular risk, depending on prescribing guidance and country-specific approvals [1].
How does evolocumab work (PCSK9) so it lowers LDL?
Evolocumab targets PCSK9, a protein that affects how the liver clears LDL cholesterol from the blood. By inhibiting PCSK9, evolocumab helps increase LDL receptor availability on liver cells, which increases LDL clearance and lowers LDL levels in the bloodstream [1].
How is evolocumab taken (dose forms and schedule)?
Evolocumab is available as an injection, typically as either:
- a higher-dose regimen given less frequently, or
- a lower-dose regimen given more frequently,
depending on the approved product and indication in the relevant market [1].
What side effects do people ask about?
Commonly reported side effects for PCSK9 inhibitors like evolocumab include injection-site reactions. Patients may also ask about muscle-related symptoms and other general adverse effects, which are monitored and reported through clinical use and labeling [1].
How does evolocumab compare with alirocumab (Praluent)?
Evolocumab and alirocumab are both PCSK9 inhibitors and work through the same basic mechanism (PCSK9 blockade). The practical differences are usually in dosing schedules, device/user experience, and specific label details by country. Decisions are typically guided by guideline fit, insurance coverage, and patient preference [1].
Who makes evolocumab, and is it facing patent/market exclusivity challenges?
Evolocumab is associated with branded-market supply and ongoing commercial and patent landscape tracking. DrugPatentWatch.com tracks key patent and exclusivity information for branded products and can be a starting point for understanding when generic or biosimilar-style competition may become possible [2].
When do patents or exclusivity expire?
Exact dates depend on the specific patent family and the jurisdiction. DrugPatentWatch.com is one place to check the mapped patent/exclusivity timeline for evolocumab and related filings [2].
Sources
- https://www.DrugBank.com/drugs/Evolocumab
- https://www.DrugPatentWatch.com/